Patents by Inventor Manel Camps

Manel Camps has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 10760071
    Abstract: A system for continuous mutagenesis to facilitate directed evolution, the system including DNA polymerases carrying the novel K54E point mutation, and other point mutations including I709N, A759R, D424A (herein called K54E_LF Pol I) and this methods of use to produce and detect lines where mutagenesis is continuous and does not exhibit the usual decline in mutagenesis with sequential cloning.
    Type: Grant
    Filed: July 25, 2016
    Date of Patent: September 1, 2020
    Assignee: THE REGENTS OF THE UNIVERSITY OF CALIFORNIA
    Inventor: Manel Camps
  • Publication number: 20190330676
    Abstract: Direct detection of mutagenesis in prokaryotes by reversion of an inactivating mutation (reversion mutation assay), producing a quantitative signal for in vivo mutagenesis, may greatly reduce the amount of test chemicals and labor involved in these assays. Further, transcriptional coupling of ?-lactamase reversion and GFP, translational fusion between ?-lactamase and GFP with stop codon in GFP, and a novel dual reporter to monitor continuous mutagenesis may be used in methods described herein.
    Type: Application
    Filed: December 26, 2017
    Publication date: October 31, 2019
    Applicant: The Regents of the University of California
    Inventors: Manel CAMPS, Jennifer ALLEN
  • Publication number: 20180216097
    Abstract: A system for continuous mutagenesis to facilitate directed evolution, the system including DNA polymerases carrying the novel K54E point mutation, and other point mutations including I709N, A759R, D424A (herein called K54E_LF Pol I) and this methods of use to produce and detect lines where mutagenesis is continuous and does not exhibit the usual decline in mutagenesis with sequential cloning.
    Type: Application
    Filed: July 25, 2016
    Publication date: August 2, 2018
    Applicant: The Regents of the University of California
    Inventor: Manel CAMPS
  • Publication number: 20150276712
    Abstract: A reversion mutation assay that is unique in providing a quantitative readout for mutagenesis. This assay is based on the creation of a functional GFP-?-lactamase fusion protein as a reporter providing both antibiotic resistance and fluorescence.
    Type: Application
    Filed: June 11, 2015
    Publication date: October 1, 2015
    Applicant: THE REGENTS OF THE UNIVERSITY OF CALIFORNIA
    Inventors: Manel Camps, Jennifer Allen
  • Patent number: 9068972
    Abstract: A reversion mutation assay that is unique in providing a quantitative readout for mutagenesis. This assay is based on the creation of a functional GFP-?-lactamase fusion protein as a reporter providing both antibiotic resistance and fluorescence. This dual reporter is placed in a multicopy plasmid to increase the number of targets, with a reversion site at the N-terminus. Rare mutations at the reversion site allow read-through of the fusion protein, producing both beta-lactamase (providing antibiotic resistance) and GFP (emitting fluorescence). In the presence of carbenicillin, beta-lactamase production confers a selective advantage that allows amplification of mutant plasmids, raising the level of fluorescence emitted by GFP to levels that are detectable by fluorimetry. A window of time can be found where fluorescence is proportional to the number of mutation events at the reversion site, making fluorescence a quantitative measure of mutagenesis.
    Type: Grant
    Filed: November 2, 2010
    Date of Patent: June 30, 2015
    Assignee: THE REGENTS OF THE UNIVERSITY OF CALIFORNIA
    Inventors: Manel Camps, Jennifer Allen
  • Publication number: 20130266983
    Abstract: Super-stable plasmids useful to improve yields of large-scale recombinant gene expression.
    Type: Application
    Filed: December 14, 2011
    Publication date: October 10, 2013
    Applicant: The Regents of The University of California
    Inventors: Manel Camps, Samuel Million-Weaver
  • Publication number: 20120302461
    Abstract: A reversion mutation assay that is unique in providing a quantitative readout for mutagenesis. This assay is based on the creation of a functional GFP-?-lactamase fusion protein as a reporter providing both antibiotic resistance and fluorescence. This dual reporter is placed in a multicopy plasmid to increase the number of targets, with a reversion site at the N-terminus. Rare mutations at the reversion site allow read-through of the fusion protein, producing both beta-lactamase (providing antibiotic resistance) and GFP (emitting fluorescence). In the presence of carbenicillin, beta-lactamase production confers a selective advantage that allows amplification of mutant plasmids, raising the level of fluorescence emitted by GFP to levels that are detectable by fluorimetry. A window of time can be found where fluorescence is proportional to the number of mutation events at the reversion site, making fluorescence a quantitative measure of mutagenesis.
    Type: Application
    Filed: November 2, 2010
    Publication date: November 29, 2012
    Applicant: The Regents of the University of California, Office of Technology Transfer
    Inventors: Manel Camps, Jennifer Allen